12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Asfotase alfa: Additional Phase II data

Additional data from an open-label, North American Phase II trial in 13 patients ages 5-12 showed that ENB-0040 met the primary endpoint of significantly improving rickets as assessed by skeletal radiographs of the wrists and knees at 6 months vs. a matched historical control group (n=17; 69% vs. 12%, p=0.002). One patient discontinued the trial due to...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >